Evidence map›Paper›PMID 38447546›Full record

ArticlePathobiology : journal of immunopathology, molecular and cellular biology2024

Cytomorphological Disparities in Invasive Breast Cancer Cells following Neoadjuvant Endocrine Therapy and Chemotherapy.

Hideko Hoshina, Takashi Sakatani, Yoko Kawamoto, Ryuji Ohashi, Hiroyuki Takei

Open access · greenAbstract read
In one paragraph

Article in Pathobiology : journal of immunopathology, molecular and cellular biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Hideko HoshinaDepartment of Breast Surgery and Oncology, Nippon Medical School, Tokyo, Japan, s8083@nms.ac.jp.
Takashi SakataniDepartment of Diagnostic Pathology, Nippon Medical School Hospital, Tokyo, Japan.
Yoko KawamotoDepartment of Integrated Diagnostic Pathology, Nippon Medical School, Tokyo, Japan.
Ryuji OhashiDepartment of Integrated Diagnostic Pathology, Nippon Medical School, Tokyo, Japan.
Hiroyuki TakeiDepartment of Breast Surgery and Oncology, Nippon Medical School, Tokyo, Japan.
Nippon Medical School · JPNippon Medical School Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionNeoadjuvant endocrine therapy (NAE) offers a breast-conserving surgery rate and clinical response rate similar to those of neoadjuvant chemotherapy (NAC), while presenting fewer adverse events and lower pathological complete response rates. The assessment of pathological response determines degenerative changes and predicts the prognosis of breast cancer treated with NAC. This study clarified the degenerative changes occurring in breast cancer following NAE.

methodsOur study encompassed two groups: NAE, consisting of 15 patients, and NAC, comprising 18 patients. Tissue samples were obtained from core needle biopsies and surgeries. Nuclear and cell areas were calculated using Autocell analysis. Furthermore, we assessed markers associated with microtubule depolymerization (KIF2A) and initiators of apoptosis (caspase-9).

resultsIn the NAC group, we observed significant increases in both cytoplasmic and cell areas. These changes in cytoplasm and cells were notably more pronounced in the NAC group compared to the NAE group. After treatment, KIF2A exhibited a decrease, with the magnitude of change being greater in the NET group than in the NAC group. However, no discernible differences were found in caspase-9 expression between the two groups.

conclusionOur findings indicate that NAE induces condensation in cancer cells via cell cycle arrest or apoptosis. Conversely, NAC leads to cell enlargement due to the absence of microtubule depolymerization. These discrepancies underscore the importance of accounting for these distinctions when establishing criteria for evaluating pathological responses.

Indexed as

Breast NeoplasmsKinesinsNeoadjuvant TherapyAdultAgedAntineoplastic Agents, HormonalApoptosisCaspase 9Chemotherapy, AdjuvantFemaleHumansMiddle AgedAntineoplastic Agents, HormonalCaspase 9KinesinsKinesin motor proteins (KIF) 2AMicrotubule depolymerizationMorphological changeNeoadjuvant endocrine therapyPathological response

Identifiers

PMID38447546
PMCPMC11309077
OpenAlexW4392682816

What Socratic holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.